Kymera Therapeutics, Inc. (KYMR)

NASDAQ: KYMR · IEX Real-Time Price · USD
31.82
-1.47 (-4.42%)
Jun 17, 2024, 4:00 PM EDT - Market closed
-4.42%
Market Cap 1.95B
Revenue (ttm) 79.41M
Net Income (ttm) -154.59M
Shares Out 61.36M
EPS (ttm) -2.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 676,354
Open 33.00
Previous Close 33.29
Day's Range 31.19 - 33.21
52-Week Range 9.60 - 45.31
Beta 2.26
Analysts Buy
Price Target 42.70 (+34.19%)
Earnings Date Aug 1, 2024

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 21, 2020
Employees 187
Stock Exchange NASDAQ
Ticker Symbol KYMR
Full Company Profile

Financial Performance

In 2023, KYMR's revenue was $78.59 million, an increase of 67.84% compared to the previous year's $46.83 million. Losses were -$146.96 million, -5.07% less than in 2022.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $42.7, which is an increase of 34.19% from the latest price.

Price Target
$42.7
(34.19% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma

4 days ago - GlobeNewsWire

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML

17 days ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming June Investor Conferences

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted...

20 days ago - GlobeNewsWire

Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024

25 days ago - GlobeNewsWire

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting

26 days ago - GlobeNewsWire

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date

4 weeks ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted...

5 weeks ago - GlobeNewsWire

Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update

KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD  with data expected in the first half of 2025

6 weeks ago - GlobeNewsWire

Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2

WATERTOWN, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target...

7 weeks ago - GlobeNewsWire

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR's late-breaking poster session

2 months ago - GlobeNewsWire

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity  with oral small molecule profiles

3 months ago - GlobeNewsWire

Kymera Therapeutics to Participate in Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

3 months ago - GlobeNewsWire

Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

KT-474/SAR444656 (IRAK4) Phase 2 program advancing in HS and AD with data expected in first half of 2025 KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and  KT-294 (TYK2) expected to ...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22

WATERTOWN, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

4 months ago - GlobeNewsWire

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

4 months ago - GlobeNewsWire

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025

5 months ago - GlobeNewsWire

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

WATERTOWN, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

5 months ago - GlobeNewsWire

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

WATERTOWN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

5 months ago - GlobeNewsWire

Kymera Therapeutics Announces Proposed Public Offering

WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

5 months ago - GlobeNewsWire

R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Company's focus on advancing first-in-class oral degraders with biologics-like activity to address areas of significant patient need and market potential

5 months ago - GlobeNewsWire

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

WATERTOWN, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targete...

6 months ago - GlobeNewsWire

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

Company to provide update on its emerging pipeline of high-value immunology programs Company to provide update on its emerging pipeline of high-value immunology programs

6 months ago - GlobeNewsWire

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

STAT3 Degrader KT-333 showed early signs of antitumor activity across liquid and solid tumors, including major responses in cutaneous T-cell lymphoma (CTCL) and Hodgkin's lymphoma

6 months ago - GlobeNewsWire

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial in Hidradenitis Suppurativa (HS)

6 months ago - GlobeNewsWire

Soros snaps up tech stocks in Q3, but dumps some of the biggest names, along with Rivian

Soros Fund Management, the investment firm founded by billionaire George Soros, took new positions or bulked up on IPOs and a number of tech names during the third quarter.

Other symbols: RIVNARM
7 months ago - Market Watch